Brief: Mustang Bio - MB-106 Continues To Demonstrate Favorable Safety, Efficacy Profile

Mustang Bio

12/06/2023 14:32

June 12 (Reuters) - Fortress Biotech Inc  FBIO.O :
    * MUSTANG BIO ANNOUNCES UPDATED RESULTS FROM WALDENSTROM
MACROGLOBULINEMIA COHORT OF ONGOING PHASE 1/2 CLINICAL TRIAL OF
MB-106, CD20-TARGETED AUTOLOGOUS CAR T THERAPY
    * MUSTANG BIO INC: MB-106 CONTINUES TO DEMONSTRATE FAVORABLE
SAFETY AND EFFICACY PROFILE
    * MUSTANG BIO INC: OVERALL RESPONSE RATE OF 83% IN COHORT
WITH
DURABLE RESPONSES OBSERVED; ONE PATIENT REMAINS IN COMPLETE
REMISSION AT 22 MONTHS
    * MUSTANG BIO INC: ALL PATIENTS WERE REFRACTORY TO BTK
INHIBITORS,
AND NO PATIENTS HAVE STARTED NEW ANTI-WM TREATMENT AFTER MB-106

Source text for Eikon:  ID:nGNX4xFdfq 
Further company coverage:  FBIO.O 

 (Reuters.briefs@thomsonreuters.com)